Carotid atherosclerosis Circulatory System Carotid atherosclerosis
Conditions
Interventions
Patients with USPIO positive carotid plaques on MRI will be randomised into a high-dose or low-dose atorvastatin group. The high-dose statin group will receive 80 mg atorvastatin daily for 12 weeks an
Sponsors
GlaxoSmithKline (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: A subject will be eligible for inclusion in this study only if all of the following criteria are met: 1. Signed written informed consent prior to beginning study-related procedures (subject must understand the aims, investigational procedures and possible consequences of the study) 2. Male or female aged 18 to 80 years of age at screening. Female subjects must be of non-childbearing potential (post-menopausal females who have been amenorrheic >1 year, or pre-menopausal females with a documented hysterectomy or bilateral oophorectomy). 3. Positive USPIO-enhanced MRI of carotid plaque confirmed by a consultant neuroradiologist. This will be pre-defined. 4. Must either be statin naive or have been on a stable dose of a statin for =4 weeks prior to screening, with no evidence of statin intolerability
Exclusion criteria
Exclusion criteria: A subject will not be eligible for inclusion in this study if any of the following criteria apply: 1. Required continued use of non-statin lipid modifying therapies 2. History of statin intolerance 3. History of chronic viral hepatitis or other chronic hepatic disorders 4. Renal impairment 5. History of myopathy or inflammatory muscle disease 6. Doppler assessment of less than 40% stenosis during screening assessment 7. Contraindication to MRI scanning 8. Planned carotid surgery or endovascular intervention earlier than 10 weeks within the study period 9. Serum triglycerides >400 mg/dl (4.52 mmol/l) at screening 10. Patients with poorly controlled diabetes mellitus and hypertension 11. History of malignancy 12. Evidence of recent severe infection 13. Current life-threatening condition other than vascular disease 14. Alcohol or drug abuse within the past six months 15. Concomitant use of potent CYP450 3A4 inhibitors 16. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) and oral steroids therapy 17. Chronic use of immunosuppressants 18. Use of an investigational drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication 19. Any other subject the investigator deems unsuitable for the study (e.g. due to either medical reasons, laboratory abnormalities, expected study medication non-compliance, or subject?s unwillingness to comply with all study-related procedures) 20. Inability to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To establish whether inflammatory activity of the atherosclerotic plaque, as measured by USPIO-enhanced MRI, can be modified after the administration of high- or low-dose atorvastatin | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To investigate MRI-derived tensile stress in carotid plaques following the administration of high- or low-dose atorvastatin 2. To quantify changes in cerebral micro-embolisation occurring in patients with carotid plaques treated with high- and low-dose atorvastatin 3. To investigate the effects of high- and low-dose atorvastatin on selected soluble plasma biomarkers 4. To compare macrophage content as determined by USPIO/MRI with histology in carotid atheroma plaques following the administration of high or low dose atorvastatin 5. To assess appearance of new lesions on brain MRI and correlate these with USPIO uptake in the carotid plaque and micro-embolic burden 6. To assess the pharmacokinetic parameters of atorvastatin | — |
Countries
United Kingdom
Outcome results
None listed